WO2003011892A3 - Glp-1 exendin-4 peptide analogs and uses thereof - Google Patents
Glp-1 exendin-4 peptide analogs and uses thereof Download PDFInfo
- Publication number
- WO2003011892A3 WO2003011892A3 PCT/US2002/024141 US0224141W WO03011892A3 WO 2003011892 A3 WO2003011892 A3 WO 2003011892A3 US 0224141 W US0224141 W US 0224141W WO 03011892 A3 WO03011892 A3 WO 03011892A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- exendin
- polypeptide
- relates
- peptide analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/485,140 US7576050B2 (en) | 2001-07-31 | 2002-07-30 | GLP-1 exendin-4 peptide analogs and uses thereof |
DE60228972T DE60228972D1 (en) | 2001-07-31 | 2002-07-30 | GLP 1 EXENDIN 4 PEPTIDE ANALOG AND THEIR USES |
JP2003517083A JP2005501058A (en) | 2001-07-31 | 2002-07-30 | GLP-1, EXENDIN-4, peptide analogue thereof and use thereof |
EP02748271A EP1411968B1 (en) | 2001-07-31 | 2002-07-30 | Glp-1 exendin-4 peptide analogs and uses thereof |
AU2002317599A AU2002317599B2 (en) | 2001-07-31 | 2002-07-30 | GLP-1 exendin-4 peptide analogs and uses thereof |
CA2455963A CA2455963C (en) | 2001-07-31 | 2002-07-30 | Glp-1, exendin-4, peptide analogs and uses thereof |
AU2008202893A AU2008202893B2 (en) | 2001-07-31 | 2008-07-01 | GLP-1 Exendin-4 peptide analogs and uses thereof |
US12/317,042 US8278272B2 (en) | 2001-07-31 | 2008-12-18 | GLP-1, exendin-4, peptide analogs and uses thereof |
US13/594,313 US8853160B2 (en) | 2001-07-31 | 2012-08-24 | GLP-1, exendin-4, peptide analogs and uses thereof |
US14/470,528 US10941187B2 (en) | 2001-07-31 | 2014-08-27 | GLP-1, exendin-4, peptide analogs and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30907601P | 2001-07-31 | 2001-07-31 | |
US60/309,076 | 2001-07-31 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10485140 A-371-Of-International | 2002-07-30 | ||
US10/485,140 A-371-Of-International US7576050B2 (en) | 2001-07-31 | 2002-07-30 | GLP-1 exendin-4 peptide analogs and uses thereof |
US12/317,042 Continuation US8278272B2 (en) | 2001-07-31 | 2008-12-18 | GLP-1, exendin-4, peptide analogs and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003011892A2 WO2003011892A2 (en) | 2003-02-13 |
WO2003011892A3 true WO2003011892A3 (en) | 2004-02-26 |
Family
ID=23196575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/024141 WO2003011892A2 (en) | 2001-07-31 | 2002-07-30 | Glp-1 exendin-4 peptide analogs and uses thereof |
Country Status (8)
Country | Link |
---|---|
US (4) | US7576050B2 (en) |
EP (3) | EP2275117B1 (en) |
JP (3) | JP2005501058A (en) |
AT (2) | ATE408414T1 (en) |
AU (2) | AU2002317599B2 (en) |
CA (1) | CA2455963C (en) |
DE (1) | DE60228972D1 (en) |
WO (1) | WO2003011892A2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050272652A1 (en) * | 1999-03-29 | 2005-12-08 | Gault Victor A | Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity |
DE60124710T2 (en) * | 2000-06-16 | 2007-09-13 | Eli Lilly And Co., Indianapolis | ANALOG OF GLUCAGON SIMILAR PEPTIDE-1 |
CA2455963C (en) * | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
DK1463751T3 (en) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Albumin Fusion Proteins. |
CA2468700A1 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
PL1605897T3 (en) * | 2003-03-19 | 2012-12-31 | Lilly Co Eli | Polyethelene glycol link glp-1 compounds |
AU2004240630B2 (en) * | 2003-05-15 | 2010-10-07 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
US7329725B1 (en) * | 2003-10-29 | 2008-02-12 | Nastech Pharmaceutical Company Inc. | Phage displayed Trp cage ligands |
US7538185B2 (en) | 2004-01-08 | 2009-05-26 | Theratechnologies Inc. | Glucagon-like peptide-1 analogs with long duration of action |
JP5638177B2 (en) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | Pancreatic polypeptide family motif and polypeptide containing the motif |
US8076288B2 (en) | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
US7893017B2 (en) | 2004-10-07 | 2011-02-22 | Novo Nordisk A/S | Protracted GLP-1 compounds |
US8030273B2 (en) | 2004-10-07 | 2011-10-04 | Novo Nordisk A/S | Protracted exendin-4 compounds |
US20070021336A1 (en) * | 2004-12-24 | 2007-01-25 | Christen Anderson | Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
EP2390264A1 (en) | 2005-02-11 | 2011-11-30 | Amylin Pharmaceuticals Inc. | GIP analog and hybrid polypeptides with selectable propperties |
US8263545B2 (en) | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
CA2606894A1 (en) * | 2005-05-05 | 2007-02-15 | Cadila Healthcare Limited | Novel compounds as glp-i agonists |
CN100429227C (en) | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin 4 polypeptide segment |
MX2008002028A (en) * | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Hybrid polypeptides with selectable properties. |
AU2006279680B2 (en) * | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
CA2623412A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
EP2497781A1 (en) * | 2005-09-08 | 2012-09-12 | Trustees Of Tufts College | Stabilized GLP-1 analogs |
CA2622069A1 (en) * | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
SI1767545T1 (en) | 2005-09-22 | 2010-03-31 | Biocompatibles Uk Ltd | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
ES2572952T3 (en) | 2005-11-07 | 2016-06-03 | Indiana University Research And Technology Corporation | Glucagon analogs showing physiological solubility and stability |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP2004213A1 (en) * | 2006-04-03 | 2008-12-24 | Novo Nordisk A/S | Glp-1 peptide agonists |
US8288339B2 (en) * | 2006-04-20 | 2012-10-16 | Amgen Inc. | GLP-1 compounds |
ATE444741T1 (en) | 2006-05-10 | 2009-10-15 | Biocompatibles Uk Ltd | Spherical microcapsules containing GLP-1 peptides, their production and their use |
CN102274557B (en) | 2006-08-09 | 2014-12-03 | 精达制药公司 | Osmotic delivery systems and piston assemblies |
US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
CN101578102B (en) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | Glucagon analogs exhibiting enhanced solubility in physiological pH buffers |
RU2413528C2 (en) | 2007-01-18 | 2011-03-10 | Открытое Акционерное Общество "Валента Фармацевтика" | Exenatide and dalargin drug for treating diabetes, adminisration and therapy |
EP2487184A1 (en) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
EP1972349A1 (en) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | GLP-1 fusion peptides conjugated to polymer(s), their production and use |
EP1975176A1 (en) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Novel glp-1 fusion peptides, their production and use |
NZ580447A (en) | 2007-04-23 | 2011-06-30 | Intarcia Therapeutics Inc | Suspension formulations of insulinotropic peptides and uses thereof |
WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
WO2009030774A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
JP5476304B2 (en) | 2007-09-05 | 2014-04-23 | ノボ・ノルデイスク・エー/エス | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
GB0717399D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission |
GB0717388D0 (en) | 2007-09-07 | 2007-10-17 | Uutech Ltd | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission |
AU2008318876B2 (en) | 2007-10-30 | 2014-05-15 | Indiana University Research And Technology Corporation | Compounds exhibiting glucagon antagonist and GLP-1 agonist activity |
WO2009058662A2 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
US20110245173A1 (en) * | 2008-06-03 | 2011-10-06 | Bachovchin William W | Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction |
CA2727161A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
TWI474832B (en) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
EP2952202B1 (en) | 2008-06-17 | 2017-10-18 | Indiana University Research and Technology Corporation | Gip-based mixed agonists for treatment of metabolic disorders and obesity |
WO2010043566A2 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
EP2384338A4 (en) * | 2008-12-29 | 2013-01-16 | Panacea Biotec Ltd | Glp-1 analogs and uses thereof |
WO2010120476A2 (en) * | 2009-04-01 | 2010-10-21 | Amylin Pharmaceuticals, Inc. | N-terminus conformationally constrained glp-1 receptor agonist compounds |
US8992886B2 (en) * | 2009-04-06 | 2015-03-31 | Board Of Regents, The University Of Texas System | Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells |
US9150632B2 (en) | 2009-06-16 | 2015-10-06 | Indiana University Research And Technology Corporation | GIP receptor-active glucagon compounds |
US20120148586A1 (en) * | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
CA2775676C (en) | 2009-09-28 | 2016-08-16 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
AU2010317994B2 (en) | 2009-11-13 | 2014-03-06 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
PL2498802T3 (en) | 2009-11-13 | 2015-06-30 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine |
EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
MX2012008603A (en) | 2010-01-27 | 2013-01-25 | Univ Indiana Res & Tech Corp | Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity. |
MX2012013001A (en) | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity. |
BR112012028707A2 (en) | 2010-05-13 | 2019-09-24 | Univ Indiana Res & Tech Corp | glucagon compound of the peptide superfamily exhibiting g receptor activity with coupled protein, prodrug, dimer or multimer, pharmaceutical composition comprising it and method of administration thereof. |
CA2796894A1 (en) | 2010-06-24 | 2011-12-29 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
AU2010360116B2 (en) | 2010-08-30 | 2014-06-26 | Sanofi-Aventis Deutschland Gmbh | Use of AVE0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
US9023986B2 (en) | 2010-10-25 | 2015-05-05 | Hoffmann-La Roche Inc. | Glucose-dependent insulinotropic peptide analogs |
MX345501B (en) | 2010-12-16 | 2017-02-02 | Novo Nordisk As | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid. |
CA2821766A1 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
US9050347B2 (en) | 2011-01-25 | 2015-06-09 | Viviabiotech, S.L. | 1,2,4-oxadiazole derivatives as drugs modulating the GLP-1 peptide receptor |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
CN106117343B (en) | 2011-04-12 | 2020-11-03 | 诺沃—诺迪斯克有限公司 | Double acylated GLP-1 derivatives |
CA2833623A1 (en) | 2011-04-20 | 2012-10-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
WO2012177444A2 (en) | 2011-06-22 | 2012-12-27 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
WO2013030160A1 (en) | 2011-08-29 | 2013-03-07 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
AR087744A1 (en) * | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE |
KR20140097151A (en) | 2011-11-17 | 2014-08-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
US9388212B2 (en) | 2013-02-21 | 2016-07-12 | Chemical & Biopharmaceutical Laboratories Of Patras S.A. | Solid phase peptide synthesis via side chain attachment |
US10933120B2 (en) | 2012-03-22 | 2021-03-02 | Novo Nordisk A/S | Compositions of GLP-1 peptides and preparation thereof |
HUE042757T2 (en) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Compositions comprising a delivery agent and preparation thereof |
CN104487056A (en) | 2012-06-20 | 2015-04-01 | 诺和诺德A/S(股份有限公司) | Tablet formulation comprising a peptide and a delivery agent |
AR091477A1 (en) | 2012-06-21 | 2015-02-04 | Univ Indiana Res & Tech Corp | GLUCAGON ANALOGS PRESENTING GIP RECEIVER ACTIVITY |
UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
EP2928562A4 (en) * | 2012-12-06 | 2016-06-22 | Stealth Peptides Int Inc | Peptide therapeutics and methods for using same |
EP2935318A1 (en) * | 2012-12-19 | 2015-10-28 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
RU2015129788A (en) | 2012-12-21 | 2017-01-30 | Санофи | EXENDIN-4 DERIVATIVES AS GLP1 / GIP DOUBLE AGONISTS OR GLP1 / GIP / GLUCAGON TRIPLE ANGONISTS |
JP6382488B2 (en) * | 2013-02-21 | 2018-08-29 | ケミカル アンド バイオファーマシューティカル ラボラトリーズ オブ パトラ エス.エー. | Solid phase peptide synthesis via side chain bonds |
CA2929555A1 (en) | 2013-11-08 | 2015-05-14 | Baylor Research Institute | Nuclear localization of glp-1 stimulates myocardial regeneration and reverses heart failure |
CN105934257B (en) | 2013-12-06 | 2020-10-09 | 韩捷 | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
TW201609795A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | EXENDIN-4 peptide analogues as dual GLP-1/GIP receptor agonists |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
HUE062573T2 (en) | 2014-12-12 | 2023-11-28 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
EA035527B1 (en) | 2014-12-30 | 2020-06-30 | Ханми Фарм. Ко., Лтд. | Glucagon derivatives with improved stability |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
US10993993B2 (en) | 2015-05-28 | 2021-05-04 | Immunoforge Co., Ltd. | Pharmaceutical composition for treating muscle atrophy or sarcopenia including glucagon-like peptide (GLP-1) or GLP-1 receptor agonist |
KR101661332B1 (en) * | 2015-05-28 | 2016-09-29 | (의료)길의료재단 | Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1 receptor agonist |
CN113598842A (en) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | Implant placement and removal system |
AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
AR105485A1 (en) | 2015-06-30 | 2017-10-11 | Hanmi Pharm Ind Co Ltd | DERIVATIVE OF GLUCAGÓN AND A COMPOSITION THAT INCLUDES A CONJUGATE OF PROLONGED ACTION OF THE SAME |
TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
CN108697768B (en) * | 2015-12-23 | 2022-07-22 | 约翰霍普金斯大学 | Long-acting GLP-1R agonists as methods of treatment for neurological and neurodegenerative conditions |
CA3010265A1 (en) | 2015-12-31 | 2017-07-06 | Hanmi Pharm. Co., Ltd. | Long-acting conjugate of triple glucagon/glp-1/gip receptor agonist |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CA3029518A1 (en) | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
KR20210092335A (en) | 2016-10-20 | 2021-07-23 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | The method for delivering the neuroprotection polypeptide to the central nervous system |
KR20190104039A (en) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Methods Including Continuous Administration of GLP-1 Receptor Agonists and Co-administration of Drugs |
BR112020014624A2 (en) | 2018-02-02 | 2020-12-08 | Novo Nordisk A/S | SOLID COMPOSITIONS UNDERSTANDING GLP-1 AGONIST, CAPRILIC AND LUBRICANT N- (8- (2-HYDROXYBENZOIL) AMINO ACID SALT) |
CN110452952B (en) * | 2018-05-08 | 2024-01-16 | 宜昌东阳光长江药业股份有限公司 | Method for detecting bioactivity of GLP-1 analogue |
KR101921085B1 (en) | 2018-05-21 | 2018-11-22 | 이뮤노포지 주식회사 | Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor |
KR102119188B1 (en) * | 2018-11-13 | 2020-06-08 | 이뮤노포지 주식회사 | Pharmaceutical composition for treating muscle atrophy comprising glucagon like-peptide-1, GLP-1 derived peptide, or GLP-1 degradation inhibitor |
WO2020175570A1 (en) * | 2019-02-28 | 2020-09-03 | 新田ゼラチン株式会社 | Brain function regulator, and food or beverage containing same |
WO2020214012A1 (en) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | Preventive or therapeutic pharmaceutical composition for hyperlipidemia comprising triple agonist acting on all of glucagon, glp-1 and gip receptors, or conjugate thereof, and preventive or therapeutic method |
WO2020214013A1 (en) * | 2019-04-19 | 2020-10-22 | 한미약품 주식회사 | Therapeutic use, for hyperlipideamia, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof |
CN114599665A (en) | 2019-08-16 | 2022-06-07 | 应用分子转运公司 | Compositions, formulations and interleukin production and purification |
IL294631A (en) * | 2020-01-13 | 2022-09-01 | Hanmi Pharm Ind Co Ltd | Therapeutic use of longacting conjugate of triple agonist having activities to all of glucagon/glp-1/gip receptors for lung disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030231A1 (en) * | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
WO1999040788A1 (en) * | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
WO2000016797A2 (en) * | 1998-09-24 | 2000-03-30 | Eli Lilly And Company | Use of glp-1 or analogs in treatment of stroke |
US6429197B1 (en) * | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US5424286A (en) * | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
EP0658568A1 (en) | 1993-12-09 | 1995-06-21 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
GB9409496D0 (en) | 1994-05-12 | 1994-06-29 | London Health Ass | Method for improving glycaemic control in diabetes |
US5574008A (en) * | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
EP0915910B1 (en) | 1996-06-05 | 2006-01-18 | Roche Diagnostics GmbH | Exendin analogues, processes for their preparation and medicaments containing them |
US6268479B1 (en) * | 1997-03-12 | 2001-07-31 | The Trustees Of Columbia University In The City Of New York | Intracellular amyloid-beta peptide binding (ERAB) polypeptide |
EP1052994A2 (en) | 1998-02-02 | 2000-11-22 | Trustees Of Tufts College | Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
JP2002508162A (en) | 1998-02-27 | 2002-03-19 | ノボ ノルディスク アクティーゼルスカブ | GLP-1 derivative with shortened N-terminus |
EP1062229A1 (en) | 1998-03-09 | 2000-12-27 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
DE19828113A1 (en) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs of Dipeptidyl Peptidase IV Inhibitors |
AU776514B2 (en) | 1998-08-10 | 2004-09-09 | General Hospital Corporation, The | Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof |
JP2002538081A (en) | 1998-12-07 | 2002-11-12 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Analogs of GLP-1 |
BR9915961A (en) | 1998-12-07 | 2001-08-21 | Sod Conseils Rech Applic | Glp-1 analogs |
JP3136356B2 (en) | 1998-12-15 | 2001-02-19 | 農林水産省家畜衛生試験場長 | DNA encoding modified signal peptide |
EP1140145B2 (en) * | 1999-01-14 | 2019-05-15 | Amylin Pharmaceuticals, LLC | Novel exendin agonist formulations and methods of administration thereof |
JP2003518914A (en) | 1999-02-10 | 2003-06-17 | キュリス インコーポレイテッド | Methods and reagents for treating glucose metabolism disorders |
CN1191273C (en) * | 1999-05-17 | 2005-03-02 | 康久化学公司 | Long lasting insulinotropic peptides |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
EP1076066A1 (en) * | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
CN1423566A (en) | 1999-11-10 | 2003-06-11 | 武田药品工业株式会社 | Body weight gain inhibitor |
US6278018B1 (en) | 1999-12-14 | 2001-08-21 | Surmodics, Inc. | Surface coating agents |
ES2227115T5 (en) | 2000-01-10 | 2014-10-30 | Amylin Pharmaceuticals, Inc. | Use of exendins and their agonists for the treatment of hypertriglyceridemia |
WO2001060411A1 (en) * | 2000-02-18 | 2001-08-23 | Kanagawa Academy Of Science And Technology | Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance |
EP1136071A3 (en) * | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
US20020115605A1 (en) * | 2000-08-24 | 2002-08-22 | Matthew During | Novel peptide with effects on cerebral health |
SI1724284T1 (en) * | 2000-12-07 | 2009-12-31 | Lilly Co Eli | GLP-1 fusion proteins |
CA2455963C (en) | 2001-07-31 | 2017-07-04 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Glp-1, exendin-4, peptide analogs and uses thereof |
EP1532261B1 (en) * | 2002-05-24 | 2010-02-10 | Medtronic, Inc. | Methods and dna constructs for high yield production of polypeptides |
US6969702B2 (en) * | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
DOP2006000008A (en) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | COMBINED THERAPY FOR THE TREATMENT OF DIABETES AND RELATED AFFECTIONS AND FOR THE TREATMENT OF AFFECTIONS THAT IMPROVE THROUGH AN INCREASE IN THE BLOOD CONCENTRATION OF GLP-1 |
EP1940454A4 (en) | 2005-09-28 | 2012-01-04 | Ventria Bioscience | Oral formulation for enteric disorders and/or rehydration |
JP2013007734A (en) | 2011-01-17 | 2013-01-10 | Nippon Dempa Kogyo Co Ltd | External force detection device and external force detection sensor |
-
2002
- 2002-07-30 CA CA2455963A patent/CA2455963C/en not_active Expired - Lifetime
- 2002-07-30 WO PCT/US2002/024141 patent/WO2003011892A2/en active Application Filing
- 2002-07-30 AT AT02748271T patent/ATE408414T1/en not_active IP Right Cessation
- 2002-07-30 US US10/485,140 patent/US7576050B2/en active Active
- 2002-07-30 EP EP10177860.3A patent/EP2275117B1/en not_active Expired - Lifetime
- 2002-07-30 EP EP02748271A patent/EP1411968B1/en not_active Expired - Lifetime
- 2002-07-30 JP JP2003517083A patent/JP2005501058A/en not_active Revoked
- 2002-07-30 EP EP08162544A patent/EP2022505B1/en not_active Expired - Lifetime
- 2002-07-30 AT AT08162544T patent/ATE536881T1/en active
- 2002-07-30 AU AU2002317599A patent/AU2002317599B2/en not_active Expired
- 2002-07-30 DE DE60228972T patent/DE60228972D1/en not_active Expired - Lifetime
-
2008
- 2008-07-01 AU AU2008202893A patent/AU2008202893B2/en not_active Expired
- 2008-12-18 US US12/317,042 patent/US8278272B2/en not_active Expired - Lifetime
-
2009
- 2009-11-18 JP JP2009262568A patent/JP5631578B2/en not_active Expired - Lifetime
-
2012
- 2012-08-24 US US13/594,313 patent/US8853160B2/en not_active Expired - Lifetime
-
2013
- 2013-01-18 JP JP2013007734A patent/JP5695097B2/en not_active Expired - Lifetime
-
2014
- 2014-08-27 US US14/470,528 patent/US10941187B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998030231A1 (en) * | 1997-01-07 | 1998-07-16 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
WO1999040788A1 (en) * | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
WO2000016797A2 (en) * | 1998-09-24 | 2000-03-30 | Eli Lilly And Company | Use of glp-1 or analogs in treatment of stroke |
US6429197B1 (en) * | 1998-10-08 | 2002-08-06 | Bionebraska, Inc. | Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
Non-Patent Citations (2)
Title |
---|
AHREN ET AL.: "No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 137, 1997, pages 643 - 649, XP002969805 * |
DOYLE ET AL.: "Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent", ENDOCRINOLOGY, vol. 142, no. 10, 2001, pages 4462 - 4468, XP002969806 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US8969288B2 (en) | 2008-12-19 | 2015-03-03 | Indiana University Research And Technology Corporation | Amide based glucagon and superfamily peptide prodrugs |
US9156902B2 (en) | 2011-06-22 | 2015-10-13 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
Also Published As
Publication number | Publication date |
---|---|
AU2002317599B2 (en) | 2008-04-03 |
CA2455963A1 (en) | 2003-02-13 |
EP1411968A4 (en) | 2005-06-15 |
JP2013139447A (en) | 2013-07-18 |
US8853160B2 (en) | 2014-10-07 |
US10941187B2 (en) | 2021-03-09 |
US20040242853A1 (en) | 2004-12-02 |
EP2275117A1 (en) | 2011-01-19 |
AU2008202893B2 (en) | 2012-01-12 |
EP1411968A2 (en) | 2004-04-28 |
ATE536881T1 (en) | 2011-12-15 |
EP2022505A2 (en) | 2009-02-11 |
US20090253625A1 (en) | 2009-10-08 |
CA2455963C (en) | 2017-07-04 |
DE60228972D1 (en) | 2008-10-30 |
AU2008202893A1 (en) | 2008-07-24 |
US20150072930A1 (en) | 2015-03-12 |
US8278272B2 (en) | 2012-10-02 |
EP2275117B1 (en) | 2016-10-26 |
EP1411968B1 (en) | 2008-09-17 |
US20120329715A1 (en) | 2012-12-27 |
ATE408414T1 (en) | 2008-10-15 |
JP5631578B2 (en) | 2014-11-26 |
EP2022505B1 (en) | 2011-12-14 |
US7576050B2 (en) | 2009-08-18 |
EP2022505A3 (en) | 2009-05-27 |
JP2010090129A (en) | 2010-04-22 |
JP5695097B2 (en) | 2015-04-01 |
JP2005501058A (en) | 2005-01-13 |
WO2003011892A2 (en) | 2003-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003011892A3 (en) | Glp-1 exendin-4 peptide analogs and uses thereof | |
EP0997151A3 (en) | Method for administering insulinotropic peptides | |
WO2003053339A3 (en) | Insulin molecule having protracted time action | |
WO2006024275A3 (en) | Glp-1 and exendin related invention | |
EP0951910A3 (en) | Method for administering monomeric insulin analogs | |
ZA200606153B (en) | Intranasal administration of glucose-regulating peptides | |
WO2003018516A3 (en) | Glucagon-like peptide-1 analogs | |
WO1999043705A8 (en) | N-terminally truncated glp-1 derivatives | |
ATE251642T1 (en) | BIOLOGICALLY ACTIVE FRAGMENTS OF GLUCAGON-LIKE INSULINOTROPIC PEPTIDES | |
MXPA01009805A (en) | Peptide. | |
WO2005000222A3 (en) | Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins | |
WO2002048192A3 (en) | Amidated glucagon-like peptide-1 | |
HUP0100928A3 (en) | Methods for treatment of diabetes using peptide analogues of insulin | |
DK1294757T3 (en) | Glucagon-like peptide 1 analogues | |
AU2002213925A1 (en) | Use of glp-1 and flp-2 peptides for treatment of bone disorders | |
HK1070589A1 (en) | Prolanged delivery of peptides | |
WO2004100968A3 (en) | A synergistic composition for the treatment of diabetes mellitus | |
AU2003234529A8 (en) | Glp-1 gene delivery for the treatment of type 2 diabetes | |
AU2689702A (en) | Glp-1 fusion proteins | |
CY1110287T1 (en) | USE OF HUMAN PARATHYROID HORMONES | |
WO2004111078A3 (en) | Compounds that modulate the glucagon response and uses thereof | |
WO2002038129A3 (en) | Delayed-release pharmaceutical formulations containing proinsulin c-peptide | |
HUP0202755A3 (en) | C-peptide for the improved production of insulin and insulin analogues | |
WO2005117584A3 (en) | Improved transmucosal delivery of peptides and proteins | |
HUP0400464A3 (en) | Adenosine analogues for treatment of the insulin resistance syndrome and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CR CU CZ DE DK DZ EE ES FI GB GD GE GH GM HR ID IL IN IS JP KE KG KP KR KZ LC LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT TZ UA UG US UZ YU ZA Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2455963 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003517083 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002748271 Country of ref document: EP Ref document number: 2002317599 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10485140 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2002748271 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |